MDMA-Assisted Psychotherapy Will Be More Cost-Effective than Other Treatments for PTSD

MAPS Logo

Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal PLOS ONE demonstrates that MDMA-assisted psychotherapy is remarkably cost-effective when compared to currently available treatments for posttraumatic stress disorder (PTSD). It is estimated that a public healthcare payer or private insurer making MDMA-assisted psychotherapy available to 1,000 patients with PTSD would reduce general and mental health care costs by $103.2 million over 30 years.

Lead author Elliot Marseille, Dr.P.H., M.P.P., elaborates, “MDMA-assisted psychotherapy is conducted by a licensed psychologist and trained clinician over the course of twelve sessions with three sessions lasting six or more hours. The cost of that time is not inconsiderable, but in just over three years, healthcare providers will break even on the costs of mental health and general medical care. These estimates are promising yet likely too conservative: the study did not measure the value of increased productivity or lower disability payments as patients recover from PTSD and is constrained by the limited availability of data on the long-term trajectory of PTSD. Further research will be needed to determine the full financial, personal, and societal benefits of MDMA-assisted psychotherapy for PTSD.”

Read the full press release here

Share This Post

Join My Personal Newsletter ❤

Get insights and resources into awareness, well-being, productivity, technology, psychedelics and more.

More To Explore

Podcast

Collision Conference 2022 Review

Collision Conference 2022 Review about the Alpha Program, getting value from the conference, after hours events, tech privilege and more!

Don't want to chat but want to keep updated?

I'd love if you subscribed today. I promise I will only send you great, valuable content that has transformed me and helped others flourish. 

You have Successfully Subscribed!

Pin It on Pinterest

Shares